Clinical trials
Ovarian cancer clinical trials
Cancer that starts in the ovaries, often found at a later stage. We’re tracking 602 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05236686Recruiting
Surgery to remove upper abdomen lymph nodes for ovarian cancer
This trial studies whether removing lymph nodes in the upper abdomen (hepatoceliac lymph nodes) improves outcomes for people with stage III or IV ovarian, fallopian tube, or primary peritoneal cancer that has spread to those lymph nodes. It also looks at how this surgery works for people with certain types of relapse, often alongside chemotherapy.
ShanghaiAges 18–75 - NCT05739981RecruitingPhase 1/Phase 2
Immunotherapy plus chemo for newly diagnosed advanced ovarian cancer
This trial tests an immune-based treatment (IMNN-001/GEN-1) combined with standard chemotherapy given before and during surgery. It’s for people with newly diagnosed advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer to see if it can improve outcomes.
Baltimore, MarylandAges 18 years+ - NCT05659381RecruitingPhase 3
Heated belly chemo plus niraparib after interval surgery for ovarian cancer
This Phase 3 study tests whether heated chemotherapy placed inside the belly, followed by interval surgery and the maintenance medicine niraparib, can improve outcomes for certain advanced ovarian, fallopian tube, or primary peritoneal cancers. It focuses on people whose tumors are HRD/LOH positive and who can have all visible disease removed.
Duarte, CaliforniaAges 18 years+ - NCT05636111RecruitingPhase 1
Study drug lurbinectedin with weekly paclitaxel and bevacizumab
This Phase 1b trial tests how well a new cancer drug (lurbinectedin) works together with weekly paclitaxel and bevacizumab in ovarian, fallopian tube, or peritoneal cancer that has returned or worsened after platinum chemotherapy. It’s designed to find the best way to use these medicines and check for early signs of benefit and safety.
Houston, TexasAges 18 years+ - NCT05579366RecruitingPhase 1/Phase 2
Study of rinatabart sesutecan for advanced solid tumors
This trial tests an investigational drug called rinatabart sesutecan (also known as Rina-S) for people with advanced solid tumors, including ovarian, endometrial, lung, breast, and other cancers. The drug is designed to target and kill cancer cells, and the study aims to see if it is safe and effective.
Phoenix, ArizonaAges 18 years+ - NCT05489211RecruitingPhase 2
Testing a cancer drug for advanced solid tumors
This Phase 2 study tests the drug Dato-DXd (alone or with other cancer medicines) in people with advanced solid tumors. It looks for tumor shrinkage and how safely the treatment can be given.
Los Angeles, CaliforniaAges 18–130 - NCT05429970Recruiting
Reducing stress before ovarian cancer surgery with two medicines
This study tests whether giving two commonly used medicines before surgery—one that can lower stress on the body (a beta-blocker) and one that reduces inflammation (a COX-2 inhibitor)—can improve outcomes compared with standard care. It’s for people with advanced ovarian, fallopian tube, or primary peritoneal cancer who are having open surgery.
Basking Ridge, New JerseyAges 18 years+ - NCT05377996RecruitingPhase 1/Phase 2
Study drug for advanced solid tumors with tumor tissue testing
This early-stage study tests emiltatug leda-dotin (Emi-Le) in people with advanced or recurring solid cancers. It aims to see how the drug works and how safely it can be given, using tumor tissue testing to help understand who may benefit.
Phoenix, ArizonaAges 18 years+ - NCT05366881Recruiting
Blood test study to spot early cancer signal and cancer leftovers
This observational study checks whether a blood test (a “cfDNA” test) can detect early signs of cancer or small amounts of cancer left after treatment. It may help doctors use a simple blood sample to improve cancer detection and follow-up.
Duarte, CaliforniaAges 40 years+ - NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Anchorage, AlaskaAges 40–75 - NCT05316129RecruitingPhase 1
Trial of your own engineered T cells for ovarian cancer
This Phase 1 study tests whether giving your own immune cells—engineered to target the FSH receptor—can control recurrent ovarian-related cancers. It’s mainly looking at safety and early signs of activity for patients whose cancer has not responded well to standard platinum chemotherapy.
Tampa, FloridaAges 18 years+ - NCT05281471RecruitingPhase 3
Tested drug for platinum-resistant ovarian cancer with bevacizumab
This Phase 3 trial tests a treatment made of an investigational gene-based drug plus standard “platinum” chemotherapy and bevacizumab, compared with standard chemotherapy and bevacizumab. It’s for ovarian/fallopian tube/primary peritoneal cancers that have not responded to platinum chemotherapy or came back quickly.
Mobile, AlabamaAges 18 years+ - NCT05225428Recruiting
Video education program based on personal genetic result disclosure
This study tests a video-based education approach that shares information differently depending on someone’s genetic test results. It may help people better understand cancer-related genetic information and what it could mean for them.
Boston, MassachusettsAges 18 years+ - NCT05142033Recruiting
Cancer or precancer testing using DNA sequencing results
This trial helps doctors study and analyze cancer- or precancer-related DNA information. If you’re 18 or older and can consent, your results may help researchers understand the biology of your condition and guide future care.
Marshall, MinnesotaAges 18 years+ - NCT05183984RecruitingPhase 2
Niraparib plus bevacizumab after complete ovarian cancer surgery
This trial tests whether niraparib, taken after surgery, works better when combined with bevacizumab in people with advanced ovarian, fallopian tube, or primary peritoneal cancer who have no visible tumor left. It also aims to see if this approach helps prevent the cancer from coming back.
AngersAges 18–99 - NCT05129969Recruiting
Registry for advanced ovarian or endometrial cancer patients
This registry collects information from people with advanced ovarian or endometrial cancer to better understand care and outcomes. It may help researchers and doctors learn which treatments work best for different patients.
Multiple LocationsAges 18 years+ - NCT05086692RecruitingPhase 1/Phase 2
Beta-only IL-2 therapy for advanced solid tumors
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
San Diego, CaliforniaAges 18 years+ - NCT05071937RecruitingPhase 2
Talazoparib plus ZEN003694 for recurrent ovarian cancer
This Phase 2 trial tests whether combining ZEN003694 with talazoparib can slow or shrink recurrent ovarian, fallopian tube, or primary peritoneal cancer. It is designed for people who have already been treated with a PARP inhibitor before, and it may help if that cancer comes back.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05092373RecruitingPhase 1
Tumor treating device plus targeted or immune drugs for advanced cancers
This Phase 1 study tests whether a tumor treating fields device works better when added to standard cancer drugs. It may help people with advanced solid tumors in the chest or belly, especially when standard treatment didn’t work or can’t be tolerated.
Houston, TexasAges 18 years+ - NCT05039801RecruitingPhase 1
Study drug IACS-6274 tested for advanced solid tumors
This Phase 1 study tests the experimental drug IACS-6274, sometimes with bevacizumab and paclitaxel, in people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and to learn whether the treatment can shrink or control cancer for certain tumor mutation types.
Houston, TexasAges 18 years+ - NCT05051722Recruiting
Test DNA blood and tissue markers to detect gynecologic cancers
This study looks for “methylated DNA markers” (special DNA patterns) to help detect endometrial, ovarian, and cervical cancers, and to support doctors around planned procedures. It may help find cancer earlier or better sort out who needs closer treatment.
Phoenix, ArizonaAges 18 years+ - NCT04981119Recruiting
Test apheresis for CAR T manufacturing in HLA-A2 solid tumors
This trial studies how a process called apheresis is used to make CAR T cells for people with certain solid tumors. It is designed for tumors that have lost a specific immune marker (HLA-A*02), which may affect how well CAR T therapies work.
Gilbert, ArizonaAges 18 years+ - NCT04997096Recruiting
Exercise during chemo to prevent weakness from low movement
This study tests whether a structured exercise program during chemotherapy can help prevent physical decline (“immobility,” like getting weaker or moving less) in people with certain ovarian or endometrial cancers. If you’re eligible, you may be guided to exercise while receiving standard chemo, and you’ll have blood tests to track changes.
Boston, MassachusettsAges 18 years+ - NCT04918186RecruitingPhase 2
Immunotherapy for platinum-resistant ovarian, with tumor testing
This Phase 2 study tests an immunotherapy approach for women whose high-grade serous ovarian cancer came back within 6 months of platinum chemotherapy. It may help shrink tumors and improve control of the disease, but you’ll need tumor biopsies and lab/heart/lung checks to join.
Chicago, IllinoisAges 18 years+
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ovarian cancer?
- Yes. Clin2 currently lists 602 recruiting ovarian cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ovarian cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ovarian cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.